Macrophage activation syndrome

Macrophage-activation syndrome is a severe, potentially life-threatening, complication of several chronic rheumatic diseases of childhood. It occurs most commonly with systemic-onset juvenile idiopathic arthritis (SoJIA). In addition, MAS has been described in association with systemic lupus erythematosus (SLE), Kawasaki disease, and adult-onset Still's disease. It is thought to be closely related and pathophysiologically very similar to reactive (secondary) hemophagocytic lymphohistiocytosis (HLH).[1] The incidence of MAS is unknown as there is a wide spectrum of clinical manifestations, and episodes may remain unrecognized.

Macrophage activation syndrome
Other namesMAS
SpecialtyRheumatology

Signs and symptoms

The hallmark clinical and laboratory features include high fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, liver dysfunction, disseminated intravascular coagulation, hypofibrinogenemia, hyperferritinemia, and hypertriglyceridemia. Despite marked systemic inflammation, the erythrocyte sedimentation rate (ESR) is paradoxically depressed, caused by low fibrinogen levels. The low ESR helps to distinguish the disorder from a flare of the underlying rheumatic disorder, in which case the ESR is usually elevated. A bone marrow biopsy or aspirate usually shows hemophagocytosis.

Cause

In many cases a trigger is identified, often a viral infection, or a medication.[2] There is uncontrolled activation and proliferation of macrophages, and T lymphocytes, with a marked increase in circulating cytokines, such as IFN-gamma, and GM-CSF. The underlying causative event is unclear, and is the subject of ongoing research. In many cases of MAS, a decreased natural killer cell (NK-cell) function is found.

Diagnosis

A febrile patient with known or suspected sJia must be considered for macrophage activation if:

Ferritin >684 ng/ml

and any 2 of the following:

Hemoglobin <90g/L (in infants <4 weeks: <100g/L)

Platelets <100 x 109/L

Neutrophils <1.0 x 109/L

Fasting triglycerides ≥3.0 mmol/L (i.e., ≥ 265mg/dl)

Fibrinogen ≤1.5 g/L [3]

In addition, other specific markers of macrophage activation (e.g. soluble CD163), and lymphocyte activation (e.g. soluble IL-2 receptor) can be helpful. NK cell function analysis may show depressed NK function, or, flow cytometry may show a depressed NK cell population. [4]

Treatment

The best treatment for MAS has not been firmly established. Most commonly used treatments include high-dose glucocorticoids, and cyclosporine. In refractory cases treatment regimens are used similar to that in HLH.

Anakinra may also be effective.[5]

gollark: Why would you EXPOSE clothing to LIQUESCENT niTRogen?
gollark: Please note that under certain circumstances, the potatOS networking subsystem may control God.
gollark: wrong color.
gollark: Your powers are NOTHING.
gollark: And *I* am the author of the PotatOS Privacy Policy.

References
  1. Grom AA, Mellins ED (September 2010). "Macrophage activation syndrome: advances towards understanding pathogenesis". Curr Opin Rheumatol. 22 (5): 561–6. doi:10.1097/01.bor.0000381996.69261.71. PMC 4443835. PMID 20517154.
  2. Agarwal S (2011). "A rare trigger for macrophage activation syndrome". Rheumatology International. 31 (3): 405–7. doi:10.1007/s00296-009-1204-0. PMID 19834709.
  3. "Macrophage Activation Syndrome".
  4. Badugu, Srinivasarao (2010). "MACROPHAGE ACTIVATIONS SYNDROME, AN IMPORTANT DIFFERENTIAL DIAGNOSIS FOR SEPTIC SHOCK". Critical Care Medicine. 38.
  5. Canna, Scott W. (2012). "Making Sense of the Cytokine Storm". Pediatric Clinics of North America. 59 (2): 329–344. doi:10.1016/j.pcl.2012.03.002. PMC 3368378. PMID 22560573.

See also
Classification
External resources
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.